News | October 25, 2021
Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company claims that its Empagliflozin tablets are the most affordable in India
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Subscribe To Our Newsletter & Stay Updated
